Fusion Pharmaceuticals Inc. financial data

Location
Hamilton, Ontario, Canada
Fiscal year end
31 December
Latest financial report
10-Q - Q1 2024 - 07 May 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1224% % -15%
Debt-to-equity 32% % 16%
Return On Assets -37% % 4.6%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 84,865,021 shares 34%
Common Stock, Shares, Outstanding 84,865,021 shares 34%
Weighted Average Number of Shares Outstanding, Basic 83,775,652 shares 56%
Weighted Average Number of Shares Outstanding, Diluted 83,775,652 shares 56%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense $75,538,000 USD 22%
General and Administrative Expense $36,739,000 USD 18%
Operating Income (Loss) $110,237,000 USD -19%
Nonoperating Income (Expense) $6,522,000 USD 253%
Income Tax Expense (Benefit) $561,000 USD -2055%
Net Income (Loss) Attributable to Parent $104,276,000 USD -13%
Earnings Per Share, Basic -1 USD/shares 30%
Earnings Per Share, Diluted -1 USD/shares 30%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $27,790,000 USD -48%
Other Assets, Current $432,000 USD -67%
Assets, Current $220,917,000 USD 0.13%
Deferred Income Tax Assets, Net $4,366,000 USD -18%
Property, Plant and Equipment, Net $6,584,000 USD 28%
Operating Lease, Right-of-Use Asset $17,861,000 USD 0.12%
Other Assets, Noncurrent $652,000 USD -88%
Assets $323,814,000 USD 21%
Accounts Payable, Current $2,503,000 USD 31%
Employee-related Liabilities, Current $2,606,000 USD 2.9%
Liabilities, Current $20,756,000 USD 20%
Operating Lease, Liability, Noncurrent $10,573,000 USD -4.5%
Liabilities $81,983,000 USD 25%
Accumulated Other Comprehensive Income (Loss), Net of Tax $582,000 USD -585%
Retained Earnings (Accumulated Deficit) $410,429,000 USD -34%
Stockholders' Equity Attributable to Parent $241,831,000 USD 20%
Liabilities and Equity $323,814,000 USD 21%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $27,306,000 USD -7.4%
Net Cash Provided by (Used in) Financing Activities $64,011,000 USD 7.6%
Net Cash Provided by (Used in) Investing Activities $70,371,000 USD -187%
Common Stock, Shares, Issued 84,865,021 shares 34%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $33,666,000 USD -452%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $29,108,000 USD -47%
Interest Paid, Excluding Capitalized Interest, Operating Activities $1,629,000 USD 49%
Operating Lease, Liability $14,861,000 USD -5.4%
Payments to Acquire Property, Plant, and Equipment $1,334,000 USD 9.1%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent $104,773,000 USD -15%
Lessee, Operating Lease, Liability, to be Paid $24,055,000 USD -10%
Operating Lease, Liability, Current $4,288,000 USD -7.5%
Lessee, Operating Lease, Liability, to be Paid, Year Two $2,400,000 USD -6.9%
Lessee, Operating Lease, Liability, to be Paid, Year One $3,367,000 USD 8.1%
Operating Lease, Weighted Average Discount Rate, Percent 0.1 pure -9.2%
Deferred Income Tax Expense (Benefit) $405,000 USD 18%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount $9,194,000 USD -17%
Lessee, Operating Lease, Liability, to be Paid, Year Three $1,322,000 USD -43%
Lessee, Operating Lease, Liability, to be Paid, Year Four $1,290,000 USD -2.7%
Operating Lease, Payments $973,000 USD 123%
Depreciation, Depletion and Amortization $361,000 USD 32%
Share-based Payment Arrangement, Expense $13,812,000 USD 22%